Revision as of 16:36, 12 September 2011 editPotatoBot (talk | contribs)Bots51,239 editsm Stub sorting and placement of stub template(s): nervous-system-drug-stub. See approval. Report errors and suggestions at User talk:PotatoBot.← Previous edit | Latest revision as of 00:43, 18 February 2024 edit undoVastV0idInSpace0 (talk | contribs)Extended confirmed users2,405 editsNo edit summaryTag: 2017 wikitext editor | ||
(37 intermediate revisions by 25 users not shown) | |||
Line 1: | Line 1: | ||
{{Short description|Chemical compound}} | |||
{{Drugbox | {{Drugbox | ||
|Verifiedfields = changed | |||
⚫ | | |
||
|Watchedfields = changed | |||
⚫ | | |
||
⚫ | |verifiedrevid = 443223642 | ||
⚫ | | |
||
⚫ | |IUPAC_name = 2-(8,9-Dioxo-2,6-diazabicyclonon-1(7)-en-2-yl)ethylphosphonic acid | ||
⚫ | | |
||
⚫ | |image = Perzinfotel.svg | ||
⚫ | |width = 150 | ||
⚫ | |CAS_number_Ref = {{cascite|correct|??}} | ||
⚫ | |CAS_number = 144912-63-0 | ||
⚫ | |ATC_prefix = none | ||
⚫ | |PubChem = 6918236 | ||
⚫ | |DrugBank_Ref = {{drugbankcite|correct|drugbank}} | ||
⚫ | |UNII_Ref = {{fdacite|correct|FDA}} | ||
⚫ | |UNII = FX5AUU7Z8T | ||
|KEGG_Ref = {{keggcite|correct|kegg}} | |||
⚫ | |KEGG = D05447 | ||
|ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | |||
|ChemSpiderID = 5293443 | |||
⚫ | |C=9 | H=13 | N=2 | O=5 | P=1 | ||
⚫ | |smiles = C1CNC2=C(C(=O)C2=O)N(C1)CCP(=O)(O)O | ||
|StdInChI_Ref = {{stdinchicite|changed|chemspider}} | |||
|StdInChI = 1S/C9H13N2O5P/c12-8-6-7(9(8)13)11(3-1-2-10-6)4-5-17(14,15)16/h10H,1-5H2,(H2,14,15,16) | |||
|StdInChIKey_Ref = {{stdinchicite|changed|chemspider}} | |||
|StdInChIKey = BDABGOLMYNHHTR-UHFFFAOYSA-N | |||
⚫ | }} | ||
⚫ | '''Perzinfotel''' ('''EAA-090''') is a drug which acts as a potent ].<ref>{{cite journal | vauthors = Kinney WA, Abou-Gharbia M, Garrison DT, Schmid J, Kowal DM, Bramlett DR, Miller TL, Tasse RP, Zaleska MM, Moyer JA | display-authors = 6 | title = Design and synthesis of non-1(7)-en-2-yl)-ethyl]phosphonic acid (EAA-090), a potent N-methyl-D-aspartate antagonist, via the use of 3-cyclobutene-1,2-dione as an achiral alpha-amino acid bioisostere | journal = Journal of Medicinal Chemistry | volume = 41 | issue = 2 | pages = 236–46 | date = January 1998 | pmid = 9457246 | doi = 10.1021/jm970504g }}</ref> It has ] effects and has been investigated for the treatment of ],<ref>{{cite journal | vauthors = Sun L, Chiu D, Kowal D, Simon R, Smeyne M, Zukin RS, Olney J, Baudy R, Lin S | title = Characterization of two novel N-methyl-D-aspartate antagonists: EAA-090 (2-non-1(7)-en2-yl]ethylphosphonic acid) and EAB-318 (R-alpha-amino-5-chloro-1-(phosphonomethyl)-1H-benzimidazole-2-propanoic acid hydrochloride) | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 310 | issue = 2 | pages = 563–70 | date = August 2004 | pmid = 15075380 | doi = 10.1124/jpet.104.066092 | s2cid = 25505657 }}</ref> but lacks ] effects.<ref>{{cite journal | vauthors = Brandt MR, Cummons TA, Potestio L, Sukoff SJ, Rosenzweig-Lipson S | title = Effects of the N-methyl-D-aspartate receptor antagonist perzinfotel non-1(7)-en-2-yl)-ethyl]phosphonic acid] on chemically induced thermal hypersensitivity | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 313 | issue = 3 | pages = 1379–86 | date = June 2005 | pmid = 15764736 | doi = 10.1124/jpet.105.084467 | s2cid = 12989500}}</ref> Nevertheless, it shows a good safety profile compared to older drugs, although further development of this drug has been discontinued.<ref>{{cite web | title = Perzinfotel | url = http://adisinsight.springer.com/drugs/800009946 | work = Adis International Ltd. | publisher = Springer Nature Switzerland AG }}</ref> | ||
Prodrugs were developed since the oral bioavailability of perzinfotel is only around 3-5%.<ref name="BaudyButera2009">{{cite journal | vauthors = Baudy RB, Butera JA, Abou-Gharbia MA, Chen H, Harrison B, Jain U, Magolda R, Sze JY, Brandt MR, Cummons TA, Kowal D, Pangalos MN, Zupan B, Hoffmann M, May M, Mugford C, Kennedy J, Childers WE | display-authors = 6 | title = Prodrugs of perzinfotel with improved oral bioavailability | journal = Journal of Medicinal Chemistry | volume = 52 | issue = 3 | pages = 771–8 | date = February 2009 | pmid = 19146418 | doi = 10.1021/jm8011799 }}</ref> | |||
<!--Clinical data--> | |||
| tradename = | |||
| routes_of_administration = | |||
⚫ | == References == | ||
<!--Pharmacokinetic data--> | |||
{{reflist}} | |||
| metabolism = | |||
| elimination_half-life = | |||
| excretion = | |||
{{Hallucinogens}} | |||
<!--Identifiers--> | |||
{{Ionotropic glutamate receptor modulators}} | |||
⚫ | | |
||
⚫ | | |
||
⚫ | | |
||
⚫ | | |
||
⚫ | | |
||
⚫ | | |
||
⚫ | | |
||
⚫ | | |
||
<!--Chemical data--> | |||
⚫ | | |
||
| molecular_weight = 260.184 g/mol | |||
⚫ | | |
||
⚫ | }} | ||
⚫ | '''Perzinfotel''' ('''EAA-090''') is a drug which acts as a potent ].<ref>Kinney WA, Abou-Gharbia M, Garrison DT, Schmid J, Kowal DM, Bramlett DR, Miller TL, Tasse RP, Zaleska MM, Moyer JA |
||
==Synthesis== | |||
] | |||
⚫ | == References == | ||
<references/> | |||
{{Glutamate_receptor_ligands}} | |||
] | ] | ||
] | ] | ||
] | ] | ||
] | ] | ||
] | |||
] | |||
] | |||
] | |||
Latest revision as of 00:43, 18 February 2024
Chemical compound Pharmaceutical compoundClinical data | |
---|---|
ATC code |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.222.780 |
Chemical and physical data | |
Formula | C9H13N2O5P |
Molar mass | 260.186 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(what is this?) (verify) |
Perzinfotel (EAA-090) is a drug which acts as a potent NMDA antagonist. It has neuroprotective effects and has been investigated for the treatment of stroke, but lacks analgesic effects. Nevertheless, it shows a good safety profile compared to older drugs, although further development of this drug has been discontinued.
Prodrugs were developed since the oral bioavailability of perzinfotel is only around 3-5%.
References
- Kinney WA, Abou-Gharbia M, Garrison DT, Schmid J, Kowal DM, Bramlett DR, et al. (January 1998). "Design and synthesis of non-1(7)-en-2-yl)-ethyl]phosphonic acid (EAA-090), a potent N-methyl-D-aspartate antagonist, via the use of 3-cyclobutene-1,2-dione as an achiral alpha-amino acid bioisostere". Journal of Medicinal Chemistry. 41 (2): 236–46. doi:10.1021/jm970504g. PMID 9457246.
- Sun L, Chiu D, Kowal D, Simon R, Smeyne M, Zukin RS, Olney J, Baudy R, Lin S (August 2004). "Characterization of two novel N-methyl-D-aspartate antagonists: EAA-090 (2-non-1(7)-en2-yl]ethylphosphonic acid) and EAB-318 (R-alpha-amino-5-chloro-1-(phosphonomethyl)-1H-benzimidazole-2-propanoic acid hydrochloride)". The Journal of Pharmacology and Experimental Therapeutics. 310 (2): 563–70. doi:10.1124/jpet.104.066092. PMID 15075380. S2CID 25505657.
- Brandt MR, Cummons TA, Potestio L, Sukoff SJ, Rosenzweig-Lipson S (June 2005). "Effects of the N-methyl-D-aspartate receptor antagonist perzinfotel non-1(7)-en-2-yl)-ethyl]phosphonic acid] on chemically induced thermal hypersensitivity". The Journal of Pharmacology and Experimental Therapeutics. 313 (3): 1379–86. doi:10.1124/jpet.105.084467. PMID 15764736. S2CID 12989500.
- "Perzinfotel". Adis International Ltd. Springer Nature Switzerland AG.
- Baudy RB, Butera JA, Abou-Gharbia MA, Chen H, Harrison B, Jain U, et al. (February 2009). "Prodrugs of perzinfotel with improved oral bioavailability". Journal of Medicinal Chemistry. 52 (3): 771–8. doi:10.1021/jm8011799. PMID 19146418.
Ionotropic glutamate receptor modulators | |
---|---|
AMPARTooltip α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor |
|
KARTooltip Kainate receptor |
|
NMDARTooltip N-Methyl-D-aspartate receptor |
|
This drug article relating to the nervous system is a stub. You can help Misplaced Pages by expanding it. |